Quantum clinical analytics milestone at SciSparc (Nasdaq: SPRC)

Rhea-AI Filing Summary

SciSparc Ltd., through its majority-owned subsidiary NeuroThera Labs, reports a technological milestone for NeuroThera’s quantum sampling workflow platform for clinical trials data analytics. The platform has demonstrated a complete end-to-end hybrid quantum-classical workflow in a quantum simulation environment using real-world clinical data.

The workflow integrates secure data ingestion and preparation, quantum-enabled analytical processing, and generation of biologically and clinically interpretable insights. It is designed to handle complex, high-dimensional biomedical datasets and apply quantum-inspired and quantum-enabled methods. Ongoing development plans include scaling supported datasets, optimizing quantum algorithms, and running performance studies, advanced through CliniQuantum Ltd., in which NeuroThera holds 54.01%.

Key Figures

Ownership in CliniQuantum Ltd.: 54.01% Announcement date: July 31, 2026 Investor relations phone: +972-3-6167055

3 metrics

Ownership in CliniQuantum Ltd. 54.01% NeuroThera’s equity interest in CliniQuantum Ltd.

Announcement date July 31, 2026 Date of the SciSparc and NeuroThera Labs quantum platform milestone announcement

Investor relations phone +972-3-6167055 Contact number provided for SciSparc investor inquiries

Key Terms

hybrid quantum-classical workflow, quantum-enabled analytical processing, continuous probability distributions, clinical trial analytics, +1 more

5 terms

hybrid quantum-classical workflow technical

"demonstrates complete end-to-end hybrid quantum-classical workflow for clinical data analytics"

A hybrid quantum-classical workflow is a computing process that splits a problem into parts handled by a quantum processor and parts handled by a conventional (classical) computer, with the two systems exchanging data and iterative results. Like a hybrid car that switches between electric and gasoline power to get the best performance, this setup lets each type of processor do what it does best. Investors care because the approach shapes how quickly and cost-effectively quantum advantages might reach real-world applications, affecting companies’ technology value, partnerships, and development timelines.

quantum-enabled analytical processing technical

"through quantum-enabled analytical processing, to the generation of biologically and clinically interpretable insights"

continuous probability distributions technical

"quantum-enhanced sampling for continuous probability distributions relevant to advanced statistical analyses"

A family of mathematical models that describe the likelihood of different outcomes for variables that can take any value within a continuous range, using a probability density function where probability is defined over intervals rather than single points. They matter to investors because analysts and risk models use them to represent things like asset returns, interest rates, or forecast errors — like a smooth hill showing which outcomes are more or less likely and helping quantify risk and expected outcomes.

clinical trial analytics medical

"quantum computing technologies to clinical research, clinical trial analytics and precision medicine applications"

precision medicine applications medical

"evaluate the potential contribution of quantum computing technologies to clinical research, clinical trial analytics and precision medicine applications"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/31/2026 - 09:15 AM Accepted by SEC EDGAR 07/31/2026 - 09:15 AM Learn about SEC filing dates

FAQ

What milestone did SciSparc (SPRC) announce regarding NeuroThera Labs' quantum platform?

SciSparc announced that NeuroThera Labs’ platform demonstrated a complete end-to-end hybrid quantum-classical workflow for clinical data analytics in a quantum simulation environment, processing real-world clinical data from secure ingestion through analysis to interpretable biomedical and clinical insights.

How is NeuroThera’s quantum platform intended to be used in SciSparc (SPRC)’s business?

The platform is designed to enable quantum-enhanced sampling for continuous probability distributions in advanced statistical analyses of clinical trial and biomedical datasets, supporting high-dimensional data and uncovering non-obvious patterns aligned with downstream scientific and clinical interpretation needs.

What role does CliniQuantum Ltd. play in SciSparc (SPRC)’s quantum initiative?

CliniQuantum Ltd. is a quantum-focused technology initiative developing proprietary computational solutions for complex clinical data analytics. NeuroThera holds a 54.01% interest in CliniQuantum, and the quantum platform is being advanced through this entity as part of SciSparc’s broader development efforts.

What therapeutic programs is SciSparc (SPRC) currently pursuing alongside its quantum data efforts?

SciSparc, through NeuroThera, focuses on cannabinoid-based pharmaceuticals, including SCI-110 for Tourette syndrome and Alzheimer’s disease agitation, and SCI-210 for autism spectrum disorder and status epilepticus, while also owning a subsidiary selling hemp seed oil-based products on Amazon.com.

What future development steps are planned for NeuroThera’s quantum platform at SciSparc (SPRC)?

Planned steps include expanding dataset scale, further optimizing the platform’s quantum algorithms, and conducting performance studies to evaluate how quantum computing technologies may contribute to clinical research, clinical trial analytics, and precision medicine applications, according to the company’s forward-looking statements.

What risks does SciSparc (SPRC) highlight regarding statements about the quantum platform?

SciSparc characterizes these as forward-looking statements subject to risks and uncertainties. It references risk factors discussed in its Annual Report on Form 20-F and later SEC filings, noting actual results could differ materially from current expectations.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of July 2026 (Report No. 3)

Commission File Number: 001-38041

SCISPARC LTD.

(Translation of registrant’s name into English)

20 Raul Wallenberg Street, Tower A,

Tel Aviv 6971916 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒     Form 40-F ☐

CONTENTS

On July 31, 2026, SciSparc Ltd. (the “Company”) issued a press release titled “SciSparc: Subsidiary NeuroThera Labs’ Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics.” A copy of this press release is furnished herewith as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “Report”) and is incorporated by reference herein.

This Report is incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-248670, 333-255408, 333-293167 and 333-293533) and on Form S-8 (File Nos. 333-278437, 333-225773, 333-286791 and 333-292952) filed with the Securities and Exchange Commission to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

1

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press release issued by SciSparc Ltd. titled “SciSparc: Subsidiary NeuroThera Labs’ Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics.”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SCISPARC LTD.
	By:	/s/ Oz Adler
	Name:	Oz Adler
	Title:	Chief Executive Officer and Chief Financial Officer

Date: July 31, 2026

3

Exhibit 99.1

SciSparc: Subsidiary NeuroThera Labs’ Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics

TEL AVIV, Israel, July 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced another technological milestone achieved by NeuroThera’s quantum sampling workflow platform for clinical trials data analytics (the “Platform”).

The Platform has successfully demonstrated a complete end-to-end hybrid quantum-classical workflow capable of processing real-world clinical data through a fully integrated analytical framework, from secure data ingestion and preparation, through quantum-enabled analytical processing, to the generation of biologically and clinically interpretable insights. The workflow was executed within a quantum simulation environment designed to emulate quantum computational processes relevant to the Platform’s analytical architecture.

The Platform’s proprietary analytical framework is designed to enable quantum-enhanced sampling for continuous probability distributions relevant to advanced statistical analyses of clinical trial and biomedical datasets.

This milestone confirms that the Platform can support a complete hybrid quantum-classical analytical workflow designed to address complex, high-dimensional biomedical datasets while applying quantum-inspired and quantum-enabled methodologies to uncover non-obvious patterns, all while maintaining alignment with downstream scientific interpretation requirements.

Building on this milestone, the Platform’s development plan includes expanding the scale of supported datasets, further optimizing its quantum algorithms, and conducting performance studies designed to evaluate the potential contribution of quantum computing technologies to clinical research, clinical trial analytics and precision medicine applications.

The Platform is being advanced through CliniQuantum Ltd., a quantum-focused technology initiative developing proprietary computational solutions for complex clinical data analytics, in which NeuroThera holds 54.01%.

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

About NeuroThera Labs Inc.

NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the anticipated capabilities, performance, scalability and utility of NeuroThera’s quantum platform and of the validated quantum sampling workflow; the continued development of the Platform through CliniQuantum Ltd. and expanding the scale of supported datasets, further optimizing its quantum algorithms and conducting performance studies designed to evaluate the potential contribution of quantum computing technologies to clinical research, clinical trial analytics and precision medicine applications. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: SUBSIDIARY NEUROTHERA LA 9.8 KB